Jazz Pharmaceuticals PLC $JAZZ is Systematic Financial Management LP’s 5th Largest Position

Posted by Brian Himes on May 24th, 2026

Systematic Financial Management LP increased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 0.6% in the 4th quarter, Holdings Channel reports. The firm owned 396,877 shares of the specialty pharmaceutical company’s stock after buying an additional 2,536 shares during the period. Jazz Pharmaceuticals makes up 1.6% of Systematic Financial Management LP’s holdings, making the stock its 5th biggest holding. Systematic Financial Management LP’s holdings in Jazz Pharmaceuticals were worth $67,469,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Capital World Investors lifted its holdings in shares of Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after purchasing an additional 10,345 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after purchasing an additional 145,865 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $127,344,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 0.2%

JAZZ opened at $239.83 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The business has a 50 day moving average price of $202.44 and a two-hundred day moving average price of $179.99. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $243.32. The company has a market cap of $15.05 billion, a PE ratio of -11,985.51, a P/E/G ratio of 0.43 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion for the quarter. As a group, research analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 5,343 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,015 shares of company stock worth $14,180,486 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on JAZZ. Raymond James Financial reaffirmed an “outperform” rating and set a $239.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Barclays upped their price objective on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.53.

Read Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.